Delfi Diagnostics Revenue and Competitors
Estimated Revenue & Valuation
- Delfi Diagnostics's estimated annual revenue is currently $47.1M per year.
- Delfi Diagnostics's estimated revenue per employee is $193,750
- Delfi Diagnostics's total funding is $105.5M.
Employee Data
- Delfi Diagnostics has 243 Employees.
- Delfi Diagnostics grew their employee count by -9% last year.
Delfi Diagnostics's People
Name | Title | Email/Phone |
---|---|---|
1 | Founder & CEO | Reveal Email/Phone |
2 | Founder and Board Directors | Reveal Email/Phone |
3 | Head People | Reveal Email/Phone |
4 | Head People | Reveal Email/Phone |
5 | Controller | Reveal Email/Phone |
6 | VP Data Science | Reveal Email/Phone |
7 | VP Technology Development | Reveal Email/Phone |
8 | VP Quality Regulatory & Lab Operations | Reveal Email/Phone |
9 | Head Translational Science | Reveal Email/Phone |
10 | Head Computational Biology and Co-founder | Reveal Email/Phone |
Delfi Diagnostics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $0.3M | 2 | -60% | N/A | N/A |
#2 | $2.9M | 38 | -31% | $17.5M | N/A |
#3 | $2.9M | 38 | -33% | $10.5M | N/A |
#4 | $19.8M | 128 | 0% | $69.4M | N/A |
#5 | $9.6M | 62 | -15% | N/A | N/A |
#6 | $1.4M | 9 | 0% | N/A | N/A |
#7 | $2.5M | 16 | 0% | N/A | N/A |
#8 | $7.4M | 48 | 0% | N/A | N/A |
#9 | $0.2M | 1 | -83% | N/A | N/A |
#10 | $1.7M | 11 | 22% | N/A | N/A |
What Is Delfi Diagnostics?
DELFI uses artificial intelligence and whole genome sequencing to sensitively detect unique patterns of DNA fragmentation in the blood of patients with cancer.
keywords:N/A$105.5M
Total Funding
243
Number of Employees
$47.1M
Revenue (est)
-9%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Delfi Diagnostics News
Delfi Founder and CEO Elected to the Fellows of the AACR Academy Class of 2022. BALTIMORE, April 4, 2022 /PRNewswire/ -- Delfi Diagnostics,...
BALTIMORE, March 30, 2022 /PRNewswire/ -- Delfi Diagnostics, a pioneering developer of a new class of high-performance, affordable liquid...
Like Delfi and PGDx, Capsulomics is an early detection cancer diagnostics company. The company, founded in 2019, has developed a single test to...
Fran Benjamin Contributor Share on Twitter Fran Benjamin is managing partner at Good Works Consulting. Monique Cadle Contributor Monique Cadle is founding partner at Good Works Consulting and VP of people at Delfi Diagnostics. In the tech industry, diversity is a hot topic. We’ve seen compa ...
Delfi Diagnostics, Inc., a Baltimore-based developer of a new class of high performance, affordable liquid biopsy tests for early cancer detection, raised $100m in Series A funding. The round was led by OrbiMed, with participation from existing investors including Menlo Ventures, Samsara Biocap ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $72.2M | 243 | -2% | N/A |
#2 | $15M | 243 | 3% | N/A |
#3 | $77M | 244 | 4% | N/A |
#4 | $67.4M | 244 | -3% | N/A |
#5 | $32.5M | 246 | 6% | N/A |